Skip to main content
UniHealth
Find my savings

Doctor search

Paul D Blumenthal, MD

Obstetrics/Gynecology · Stanford

NPI 1336202977

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
5
2 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Plans that list them

5 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Blumenthal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

5 of 5 plans

Plans whose provider directory lists this clinician
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G47601 · Current

Licensed to practise in California · since 1982 · expires 2028-03-31 · Rosalind Franklin University, the Chicago Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Money from drug and device companies

$10,157 in 2024

Industry payments by year
202418$8,333$10,157
202211$1,506$1,506
202111$9,000$9,000
201911None$59

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Bayer Healthcare PharmaceuticalsKyleena$10,157
8 payments
  • Travel for Kyleena · 2024-10-19 · $161
  • Travel for Kyleena · 2024-10-18 · $289
  • Travel for Kyleena · 2024-10-18 · $588
  • Meals for Kyleena · 2024-10-18 · $48
  • Meals for Kyleena · 2024-10-18 · $48
  • Meals for Kyleena · 2024-10-18 · $101
  • Consulting for Kyleena · 2024-10-18 · $8,333
  • Travel for Kyleena · 2024-10-17 · $588
See all 8 published payments
Every published payment
Bayer Healthcare PharmaceuticalsTravel · 2024-10-19Kyleena$161
Bayer Healthcare PharmaceuticalsTravel · 2024-10-18Kyleena$289
Bayer Healthcare PharmaceuticalsTravel · 2024-10-18Kyleena$588
Bayer Healthcare PharmaceuticalsMeals · 2024-10-18Kyleena$48
Bayer Healthcare PharmaceuticalsMeals · 2024-10-18Kyleena$48
Bayer Healthcare PharmaceuticalsMeals · 2024-10-18Kyleena$101
Bayer Healthcare PharmaceuticalsConsulting · 2024-10-18Kyleena$8,333
Bayer Healthcare PharmaceuticalsTravel · 2024-10-17Kyleena$588
See earlier years (2022, 2021, 2019)

2022: $1,506

Payments by company in 2022
Bayer HealthCare PharmaceuticalsKyleena$1,506
1 payment
  • Consulting for Kyleena · 2022-02-10 · $1,506

2021: $9,000

Payments by company in 2021
HRA PharmaNone$9,000
1 payment
  • Consulting · 2021-07-02 · $9,000

2019: $59

Payments by company in 2019
Merck Sharp & DohmeNexplanon$59
1 payment
  • Meals for Nexplanon · 2019-10-19 · $59

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Sebela Pharmaceuticals Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Veracept, A Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability · 2019Their institution$259,978
Organon LLC · A Study To Assess Contraceptive Efficacy and Safety of Etonogestrel (Eng) Implant Beyond 3 Years of Use (Mk-8415-060) · 2022Their institution$139,618
Organon LLC · Efficacy and Safety of Nexplanon 36 To 60 Months Post Insertion · 2023Their institution$139,171
Sebela Pharmaceuticals Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Veracept, A Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability · 2020Their institution$101,137
Organon LLC · 8415-8415-060-Pn060-Extended Duration Study (Celanese + 2 Years)-Contraception-Sc-Imp-Supplemental Registration-USA-Ld-B · 2021Their institution$65,023
Sumitomo Pharma America, Inc. · A Phase 3 Singlearm Openlabel Study To Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 To 50 Years of Age and at Risk for Pregnancy · 2024Their institution$57,001
Sebela Women's Health Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Veracept, A Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability · 2022Their institution$56,140
Organon LLC · A Phase 3, Open-Label, Multi-Center, Single Arm Study To Assess Contraceptive Efficacy and Safety of the Etonogestrel Mk-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age Or Younger · 2021Their institution$53,912
Mylan Inc. · Mr-100a-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100a-01 in Women of Childbearing Potential To Evaluate Contraceptive Efficacy and Safety · 2023Their institution$52,694
Organon LLC · 2024Their institution$48,029
Sebela Women's Health Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Veracept, A Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability · 2024Their institution$46,589
Sebela Pharmaceuticals Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Veracept, A Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability · 2021Their institution$41,040
Medicines360 · A Study of A Levonorgestrelreleasing Intrauterine System for Longterm, Reversible Contraception · 2019Their institution$38,078
Mylan Inc. · Mr-100a-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100a-01 in Women of Childbearing Potential To Evaluate Contraceptive Efficacy and Safety · 2024Their institution$35,984
Sebela Women's Health Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Veracept, A Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability · 2023Their institution$34,071
Merck Sharp & Dohme Corporation · A Phase 3, Open-Label, Multi-Center, Single Arm Study To Assess Contraceptive Efficacy and Safety of the Etonogestrel Mk-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age Or Younger · 2021Their institution$33,785
Sumitomo Pharma America, Inc. · Serene · 2023Their institution$33,045
Sebela Women's Health Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Veracept, A Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability · 2025Their institution$32,133
Medicines360 · A Phase 3 Multicenter, Open-Label Study of A Levonorgestrel 52 Mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding · 2019Their institution$29,710
Sumitomo Pharma America, Inc. · A Phase 3b Study To Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis · 2025Their institution$26,056
Sumitomo Pharma America, Inc. · A Phase 3, Single-Arm, Open-Label Study To Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 To 50 Years of Age and at Risk for Pregnancy · 2025Their institution$25,846
Medicines360 · A Phase 3 Multicenter, Open-Label Study of A Levonorgestrel 52 Mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding · 2021Their institution$23,184
Organon LLC · 2022Their institution$22,794
Sumitomo Pharma America, Inc. · A Phase 3, Single-Arm, Open-Label Study To Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 To 50 Years of Age and at Risk for Pregnancy · 2023Their institution$19,714
Myovant Sciences GmbH · Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis · 2022Their institution$19,580
Sumitomo Pharma America, Inc. · A Phase 3b Study To Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis · 2024Their institution$19,580
Medicines360 · A Phase 3 Multicenter, Open-Label Study of A Levonorgestrel 52 Mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding · 2020Their institution$17,533
Bayer HealthCare Pharmaceuticals Inc. · Bay86-5028 Mirena Extension Contraception · 2020Their institution$14,358
Bayer HealthCare Pharmaceuticals Inc. · Bay86-5028 Mirena Extension Contraception · 2021Their institution$13,857
Organon Llc · 2025Their institution$11,652
Mylan Inc. · Mr-100a-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100a-01 in Women of Childbearing Potential To Evaluate Contraceptive Efficacy and Safety · 2025Their institution$11,354
Medicines360 · A Study of A Levonorgestrelreleasing Intrauterine System for Longterm, Reversible Contraception · 2022Their institution$10,299
Bayer HealthCare Pharmaceuticals Inc. · Bay86-5028 Mirena Extension Contraception · 2019Their institution$8,501
Sebela Women's Health Inc. · A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study To Evaluate Levocept, A Long-Acting Reversible Intrauterine System for Contraceptive Efficacy, Safety, and Tolerability · 2025Their institution$3,914
Medicines360 · A Study of A Levonorgestrelreleasing Intrauterine System for Longterm, Reversible Contraception · 2020Their institution$661

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1336202977
Licence
CA G47601California G47601: Current · expires 2028-03-31
Trained
R Franklin University of Med & Sci/Chicago Medical School, 1977
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 1336202977
Taxonomy
Federal specialty code 207VC0300X (207VC0300X); Federal specialty code 207V00000X (207V00000X)
Mailing address
2680 Hanover St, Palo Alto, CA, 94304
NPI first listed
2006-12-18
NPI last updated
2024-04-19
NPI record certified
2024-04-19

This is when the NPI record was last certified, not a medical board exam.